Biotech firm launches TIL 2.0, causing tumors to quiver, according to debut announcement

Asia Bio Innovation Summit 2025: Paving the Way for the Future of Biopharma

The Asia Bio Innovation Summit 2025, held in Singapore on August 22, 2025, proved to be a significant event in the biopharmaceutical industry. The summit, which lasted for two days, brought together experts from regulatory authorities, big pharma, biotech, academia, CXO, and other sectors to discuss the latest advancements and challenges in the field.

One of the keynote presentations was delivered by Dr. Mingyu Liu, Senior R&D Scientist at Biosyngen. His talk, titled "Next-Generation TIL Therapies: Challenges and Strategies," focused on the development of these innovative treatments and the strategies to overcome the hurdles in their development.

TIL (Tumour Infiltrating Lymphocytes) therapy, a type of cancer immunotherapy, has shown promise in the treatment of certain cancers such as advanced melanoma and cervical cancer. However, Dr. Liu emphasised the need to further unlock its efficacy in other solid tumors.

Biosyngen, a company at the forefront of TIL therapy development, shared their strategic approach during the summit. This includes a high-efficiency TIL expansion process, which allows for robust TIL expansion from both surgical resection samples and biopsy samples. This approach is intended to improve clinical response rates.

Moreover, Biosyngen utilises a lentiuret transfection system for stable genetic modification of TILs, enhancing their antitumor activity. The transduction efficiency of this genetic modification process exceeds 50%.

The company also enriches antigen-specific T cells through the use of specific biomarkers or selective expansion techniques. This approach is aimed at improving the efficacy of TIL therapy.

The summit also highlighted the focus on antibody-drug conjugates (ADCs) and cell and gene therapies (CGT). A prevailing consensus among experts is that these technologies will serve as key drivers of oncology innovation over the next decade.

The Asia BIO Innovation Summit facilitates cross-border knowledge exchange and cutting-edge technology sharing. The event brought together 30+ world-class speakers, 10+ exhibitors, and 200+ attendees.

The summit has strengthened global collaboration and injected fresh momentum into the leapfrog development of Asia's biopharma industry. The Chengdu and Shenzhen editions of the Asia Bio Innovation Summit will take place in late August, focusing on regional biopharma policies, innovation ecosystem development, and industry-academia collaboration.

Asia's biopharma industry is rapidly emerging as the new global powerhouse for biopharmaceutical breakthroughs, and events like the Asia Bio Innovation Summit are playing a crucial role in accelerating this growth.